Category Archives: Ulcerative Colitis

Currently, the main targets of drug therapy for ulcerative colitis [UC] are endoscopic and clinical remission. However, there is active discussion about the additional advantages of including histological remission as a target. Accumulating evidence indicates that microscopic activity persists in endoscopically quiescent UC, that histological changes may lag behind clinical remission after treatment, and that absence of histological activity predicts lower rates of relapse, hospitalisation, surgery, and subsequent neoplasia Continue reading →

CONCORD, Mass.--(BUSINESS WIRE)--Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, announced today FDAs Clearance of the IND for BT051, and initiation of a Phase 1 Clinical Trial with patient dosing expected in the coming months. BT051 is a first-in-class approach to modulating the migration and activation of specific innate immune cells (neutrophils) and is being developed to treat various acute medical conditions including ulcerative colitis. The advancement of BT051 into the clinic was based on its favorable profile exhibited in pre-clinical safety testing, along with its GI tract-restricted distribution and its demonstration of potent and selective activity against human primary neutrophils in a model of inflammation. Continue reading →

Positive topline results were announced from the phase 3 True North trial evaluating the efficacy of ozanimod as an induction and maintenance therapy for adults with moderate to severe ulcerative colitis. The multicenter, double-blind, placebo-controlled trial enrolled more than 1000 patients with moderate to severe ulcerative colitis who had an inadequate response to prior treatment Continue reading →

The global Ulcerative Colitis Drugs market focuses on encompassing major statistical evidence for the Ulcerative Colitis Drugs industry as it offers our readers a value addition on guiding them in encountering the obstacles surrounding the market. A comprehensive addition of several factors such as global distribution, manufacturers, market size, and market factors that affect the global contributions are reported in the study. In addition the Ulcerative Colitis Drugs study also shifts its attention with an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production, and utilized strategies are also marked. Continue reading →

NEW YORK, June 9, 2020 /PRNewswire/ --Immunic, Inc. (Nasdaq: IMUX),a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced receipt of regulatory allowance from the U.S. Food and Drug Administration (FDA) to initiate its phase 2, CALVID-1 clinical trial of IMU-838, the company's selective oral DHODH inhibitor, in coronavirus disease 2019 (COVID-19) at centers in the United States. Continue reading →

Eli Lilly and Co The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios. The report also focuses on the global industry trends, development patterns of industries, governing factors, growth rate, and competitive analysis of the market, growth opportunities, challenges, investment strategies, and forecasts till 2026. Continue reading →

A new market report by Market Research Intellect on the Drug For Ulcerative Colitis Market has been released with reliable information and accurate forecasts for a better understanding of the current and future market scenarios. The report offers an in-depth analysis of the global market, including qualitative and quantitative insights, historical data, and estimated projections about the market size and share in the forecast period. The forecasts mentioned in the report have been acquired by using proven research assumptions and methodologies Continue reading →

UpMarketResearch offers a latest published report on Global Ulcerative Colitis Immunology Drugs Market industry analysis and forecast 20192025 delivering key insights and providing a competitive advantage to clients through a detailed report. This is a latest report, covering the current COVID-19 impact on the market Continue reading →

Why not start this summer off right with Galpagos? I know what youre thinking the Galpagos Islands are quite dreamy, but what I really mean is the stock, as in Galpagos NV or $GLPG. Continue reading →

The work, which will lean into ETXs expertise in network biology and in silico phenotypic screening, will focus on approaches to modulate one specific mechanism involved in IPF and other fibrotic conditions e-therapeutics PLC(LON: ETX.L) is teaming up with Belgian life sciences giant Galapagos to uncover a new means of treating idiopathic pulmonary fibrosis, a serious lung disease with a poor prognosis. Continue reading →